[辉瑞/BioNTech新冠疫苗不良反应发生率:回顾性队列研究]。

Ana Carolina Martínez-Roa, Lázaro Labra-Rubio, Isette Yunue Landeros-Navarro
{"title":"[辉瑞/BioNTech新冠疫苗不良反应发生率:回顾性队列研究]。","authors":"Ana Carolina Martínez-Roa, Lázaro Labra-Rubio, Isette Yunue Landeros-Navarro","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronavirus SARS-CoV-2 has been the cause of multiple hospitalizations due to respiratory distress, pneumonia, multi-organic failure and death in all the world. The BioNTech/Pfizer lab was the first to get the approval from the Food and Drug Administration (FDA) for vaccine application, beginning with health workers. However, there are a few studies about adverse effects after applying the COVID-19 vaccine.</p><p><strong>Objective: </strong>To assess the presence and time of onset of adverse effects produced by the COVID-19 vaccine.</p><p><strong>Material and methods: </strong>A retrospective cohort study was carried out, including medical residents from the Hospital de Especialidades No. 1 (Specialties Hospital No. 1) from the Bajío National Medical Center, who received two doses of Pfizer-BioNTech vaccine and decided to participate voluntarily. We obtained the information by a self-assessment tool sent via email. All adverse effects were collected emphasizing those described in the literature.</p><p><strong>Results: </strong>A total of 101 medical residents were included. It was observed that 55.54% presented adverse effects after the first dose, which appeared in the first 24 hours after the vaccine was administered. After the second dose, 54.5% presented symptomatology, 41.6% during first 24 hours after the vaccine was administered.</p><p><strong>Conclusions: </strong>It was observed symptomatology after applying the complete series (two doses) of BioNTech/Pfizer; however, there were mild and of short duration.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10761190/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Adverse effect incidence of Pfizer/BioNTech COVID-19 vaccine: Retrospective cohort study].\",\"authors\":\"Ana Carolina Martínez-Roa, Lázaro Labra-Rubio, Isette Yunue Landeros-Navarro\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Coronavirus SARS-CoV-2 has been the cause of multiple hospitalizations due to respiratory distress, pneumonia, multi-organic failure and death in all the world. The BioNTech/Pfizer lab was the first to get the approval from the Food and Drug Administration (FDA) for vaccine application, beginning with health workers. However, there are a few studies about adverse effects after applying the COVID-19 vaccine.</p><p><strong>Objective: </strong>To assess the presence and time of onset of adverse effects produced by the COVID-19 vaccine.</p><p><strong>Material and methods: </strong>A retrospective cohort study was carried out, including medical residents from the Hospital de Especialidades No. 1 (Specialties Hospital No. 1) from the Bajío National Medical Center, who received two doses of Pfizer-BioNTech vaccine and decided to participate voluntarily. We obtained the information by a self-assessment tool sent via email. All adverse effects were collected emphasizing those described in the literature.</p><p><strong>Results: </strong>A total of 101 medical residents were included. It was observed that 55.54% presented adverse effects after the first dose, which appeared in the first 24 hours after the vaccine was administered. After the second dose, 54.5% presented symptomatology, 41.6% during first 24 hours after the vaccine was administered.</p><p><strong>Conclusions: </strong>It was observed symptomatology after applying the complete series (two doses) of BioNTech/Pfizer; however, there were mild and of short duration.</p>\",\"PeriodicalId\":94200,\"journal\":{\"name\":\"Revista medica del Instituto Mexicano del Seguro Social\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10761190/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista medica del Instituto Mexicano del Seguro Social\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:冠状病毒SARS-CoV-2已成为全球因呼吸窘迫、肺炎、多器官衰竭和死亡而住院的多例病例。BioNTech/辉瑞实验室是第一个获得美国食品和药物管理局(FDA)批准的疫苗申请,从卫生工作者开始。然而,关于接种新冠病毒疫苗后的不良反应的研究很少。目的:了解新型冠状病毒肺炎(COVID-19)疫苗不良反应的存在及发生时间。材料与方法:采用回顾性队列研究,研究对象为Bajío国家医疗中心第一专科医院住院医师,接受两剂辉瑞- biontech疫苗并自愿参与。我们通过电子邮件发送的自我评估工具获得信息。收集所有不良反应,强调文献中描述的不良反应。结果:共纳入住院医师101人。55.54%的人在首次接种后出现不良反应,不良反应出现在接种后24小时内。第二次接种后,54.5%的人出现症状,41.6%的人在接种疫苗后的前24小时出现症状。结论:应用BioNTech/Pfizer全系列(2剂)治疗后,观察到症状;然而,也有轻微且持续时间短的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Adverse effect incidence of Pfizer/BioNTech COVID-19 vaccine: Retrospective cohort study].

Background: Coronavirus SARS-CoV-2 has been the cause of multiple hospitalizations due to respiratory distress, pneumonia, multi-organic failure and death in all the world. The BioNTech/Pfizer lab was the first to get the approval from the Food and Drug Administration (FDA) for vaccine application, beginning with health workers. However, there are a few studies about adverse effects after applying the COVID-19 vaccine.

Objective: To assess the presence and time of onset of adverse effects produced by the COVID-19 vaccine.

Material and methods: A retrospective cohort study was carried out, including medical residents from the Hospital de Especialidades No. 1 (Specialties Hospital No. 1) from the Bajío National Medical Center, who received two doses of Pfizer-BioNTech vaccine and decided to participate voluntarily. We obtained the information by a self-assessment tool sent via email. All adverse effects were collected emphasizing those described in the literature.

Results: A total of 101 medical residents were included. It was observed that 55.54% presented adverse effects after the first dose, which appeared in the first 24 hours after the vaccine was administered. After the second dose, 54.5% presented symptomatology, 41.6% during first 24 hours after the vaccine was administered.

Conclusions: It was observed symptomatology after applying the complete series (two doses) of BioNTech/Pfizer; however, there were mild and of short duration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Multifocal motor neuropathy. Report of three cases at a reference hospital in Mexico]. [Answer to "Comment on article: "Risk factors associated with cognitive impairment in older adults: cross-sectional study""]. [Comment on article: "Risk factors associated with cognitive impairment in older adults: cross-sectional study"]. [Pulmonary Hypertension Centers]. [Severe coronavirus-2 infection background for cardiovascular complications].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1